Inari Medical FY2025 EPS Estimate Increased by William Blair

Inari Medical, Inc. (NASDAQ:NARI) – William Blair raised their FY2025 earnings per share estimates for Inari Medical in a note issued to investors on Thursday, October 31st. William Blair analyst M. Kaczor now anticipates that the company will post earnings per share of $0.18 for the year, up from their prior estimate of $0.13. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.74) per share.

NARI has been the subject of several other reports. Leerink Partnrs raised Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Stifel Nicolaus initiated coverage on Inari Medical in a report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective for the company. Wells Fargo & Company reduced their target price on Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $58.89.

Inari Medical Stock Up 0.4 %

Shares of NASDAQ:NARI opened at $48.93 on Monday. The firm has a fifty day simple moving average of $43.66 and a two-hundred day simple moving average of $46.15. Inari Medical has a 52 week low of $36.73 and a 52 week high of $67.13. The stock has a market capitalization of $2.86 billion, a P/E ratio of -36.10 and a beta of 0.96.

Insider Activity at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total transaction of $2,002,000.00. Following the transaction, the director now owns 561,233 shares in the company, valued at approximately $28,089,711.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00. Following the completion of the sale, the director now owns 561,233 shares in the company, valued at $28,089,711.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 131,000 shares of company stock worth $6,161,340. 10.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Inari Medical

A number of institutional investors have recently bought and sold shares of NARI. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Inari Medical in the 1st quarter worth about $30,000. GAMMA Investing LLC raised its stake in shares of Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares during the last quarter. Covestor Ltd lifted its position in Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after acquiring an additional 376 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.